Novo Nordisk bets $600M biobucks on NanoVation's ability to take genetic medicines beyond the liver

Novo Nordisk is continuing its push into genetic medicines, agreeing to pay NanoVation Therapeutics up to $600 million to collaborate on up to seven programs built on technology for targeting cells outside the liver.